Logo image
Myelin oligodendrocyte glycoprotein antibody-associated disorders coexisting with ankylosing spondylitis: Potential association between demyelination and tumor necrosis factor inhibitors
Journal article   Peer reviewed

Myelin oligodendrocyte glycoprotein antibody-associated disorders coexisting with ankylosing spondylitis: Potential association between demyelination and tumor necrosis factor inhibitors

W. Luo, R. Li, Y. Chang, H. She, A.G. Kermode and W. Qiu
Multiple Sclerosis and Related Disorders, Vol.51, Art. 102889
2021
url
Link to Published Version *Subscription may be requiredView

Abstract

Myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) is a newly described demyelinating disease. Ankylosing spondylitis (AS) is an inflammatory disease that predominantly affects the axial skeleton. Treatments for AS, such as tumor necrosis factor alpha (TNFα) inhibitors, may induce demyelination. We report the first case of MOGAD coexisting with AS and postulate a potential association with TNFα inhibitors. Further studies are needed to clarify the risk of demyelinating events following anti-TNFα therapy and to elucidate the relationship between MOGAD and AS.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.203 Neuromuscular Disorders
1.203.147 Multiple Sclerosis
Web Of Science research areas
Clinical Neurology
ESI research areas
Neuroscience & Behavior
Logo image